Evidence map›Paper›PMID 40664477›Full record

ArticleGenome research2025

Alternative splicing generates HER2 isoform diversity underlying antibody-drug conjugate resistance in breast cancer.

Gabriela D A Guardia, Carlos H Dos Anjos, Aline Rangel-Pozzo, Filipe F Dos Santos, Alexander Birbrair, Paula F Asprino, Anamaria A Camargo, Pedro A F Galante

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gabriela D A Guardia *Centro de Oncologia Molecular, Hospital Sírio Libanês, São Paulo 01308-050, Brazil.ORCID 0000-0002-1789-2768
Carlos H Dos Anjos *Centro de Oncologia Molecular, Hospital Sírio Libanês, São Paulo 01308-050, Brazil.ORCID 0000-0002-2815-0882
Aline Rangel-PozzoDepartment of Physiology and Pathophysiology, CancerCare Manitoba Research Institute, University of Manitoba, Winnipeg MB R3E 0J9, Canada.ORCID 0000-0001-7217-5297
Filipe F Dos SantosCentro de Oncologia Molecular, Hospital Sírio Libanês, São Paulo 01308-050, Brazil.ORCID 0000-0003-2335-463X
Alexander BirbrairDepartment of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin 53715, USA.ORCID 0000-0003-1015-2561
Paula F AsprinoCentro de Oncologia Molecular, Hospital Sírio Libanês, São Paulo 01308-050, Brazil.ORCID 0000-0002-2157-5853
Anamaria A CamargoCentro de Oncologia Molecular, Hospital Sírio Libanês, São Paulo 01308-050, Brazil.ORCID 0000-0002-6076-9597
Pedro A F GalanteCentro de Oncologia Molecular, Hospital Sírio Libanês, São Paulo 01308-050, Brazil; pgalante@mochsl.org.br.ORCID 0000-0002-4820-4155

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is a heterogeneous disease that can be molecularly classified based on the expression of the ERBB2 receptor (also known as

Indexed as

Alternative SplicingBreast NeoplasmsDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesImmunoconjugatesCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansProtein IsoformsTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesProtein IsoformsTrastuzumab

Identifiers

PMID40664477
PMCPMC12400952

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.